CD123 CAR-T (Shenzhen Geno-Immune Medical Institute)

CD123 CAR-T is an investigational chimeric antigen receptor (CAR) T-cell therapy developed by the Shenzhen Geno-Immune Medical Institute for the treatment of acute myeloid leukemia (AML). This cell-based biologic therapy involves the genetic modification of a patient's T cells using lentiviral vectors to express a CAR that specifically recognizes CD123 (interleukin-3 receptor alpha chain, IL-3Rα). CD123 is a surface antigen highly expressed on AML blasts and leukemic stem cells, making it a strategic target for eliminating the source of the malignancy. The therapy is currently being evaluated in Phase I/II clinical trials, often in combination with other CAR-T cells targeting CLL-1 or CD33 to enhance efficacy and prevent antigen escape in patients with relapsed or refractory AML.

Other names

CD123-specific CAR gene-engineered T cellsCD-123-specific CAR gene-engineered T cellsCD 123-specific CAR gene-engineered T cellsanti-CD123 CAR-T cellsanti-CD-123 CAR-T cellsanti-CD 123 CAR-T cellsCD123-targeted chimeric antigen receptor T-cell therapyCD-123-targeted chimeric antigen receptor T-cell therapyCD 123-targeted chimeric antigen receptor T-cell therapy